Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy,

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The manufacturer, Eli Lilly, says the drug, which is not yet licensed, could be available next year.

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss and higher rates of nausea and vomiting than anticipated, side effects assoc